8-K: Genprex Regains Nasdaq Bid Price Compliance

Genprex, Inc. has been formally notified that it has regained compliance with the Nasdaq Capital Market's Minimum Bid Price Requirement.

Summary

• Genprex, Inc. received formal notification on August 4, 2026, that it has regained compliance with the Nasdaq Capital Market's Minimum Bid Price Requirement.
• The company had previously been granted an exception by the Nasdaq Hearings Panel to demonstrate compliance.
• The Panel will maintain jurisdiction until December 7, 2026, during which time the company must ensure its closing bid price remains at or above $1.00 daily.
• If non-compliance with any other Listing Rule occurs before December 7, 2026, Genprex will have seven calendar days to present a cure plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating the company has successfully addressed a critical listing requirement, though continued vigilance is necessary.

Positives

• Regained compliance with the Nasdaq Capital Market's Minimum Bid Price Requirement.
• Successfully addressed a critical listing standard, avoiding immediate delisting concerns.
• Granted an exception by the Nasdaq Hearings Panel, demonstrating a path to compliance.

Negatives

• The company must maintain a closing bid price at or above $1.00 for each trading day until December 7, 2026.
• The Nasdaq Hearings Panel will maintain jurisdiction over the company until December 7, 2026.
• Any future non-compliance with other Listing Rules will trigger a strict seven-day cure period.

Risks

• Risk of failing to maintain a closing bid price at or above $1.00 for each trading day until December 7, 2026.
• Potential for non-compliance with other Nasdaq Listing Rules between now and December 7, 2026, which could lead to delisting.
• The Panel's continued jurisdiction until December 7, 2026, means ongoing scrutiny and potential for swift action on deficiencies.

Future Outlook

The company must maintain a closing bid price at or above $1.00 for each trading day until December 7, 2026. Any future non-compliance with other listing rules will result in a seven-day period to advise the Panel on a cure plan.

Management Comments

• Ryan M. Confer, President, Chief Executive Officer and Chief Financial Officer, signed the report, indicating management's acknowledgment and responsibility for the filing.

Industry Context

StockSavvy.ai notes that maintaining listing on major exchanges like Nasdaq is crucial for investor confidence and liquidity. Failure to meet bid price requirements can signal underlying business challenges or market perception issues, and regaining compliance is a significant step towards stability.

Stakeholder Impact

• Shareholders: Positive impact due to maintaining listing on Nasdaq, which supports liquidity and investor confidence. Continued compliance is essential to avoid potential delisting.
• Creditors: Positive impact as maintaining exchange listing generally supports the company's financial stability and ability to access capital markets.
• Employees: Positive impact as job security and company stability are enhanced by continued listing.

Next Steps

• Maintain a closing bid price at or above $1.00 for each trading day until December 7, 2026.
• If non-compliant with any other Listing Rule between now and December 7, 2026, advise the Panel within seven calendar days on a plan to cure the deficiency.

Key Dates

Recommendation

The filing confirms Genprex has regained compliance with the Nasdaq bid price requirement, which is a necessary step to avoid delisting and is an expected outcome given the prior exception. However, the ongoing requirement to maintain the bid price and the Panel's continued jurisdiction until December 7, 2026, indicate continued scrutiny and potential volatility. Therefore, a 'hold' recommendation is appropriate, pending further operational and financial performance improvements.

Keywords

Nasdaq Compliance, Bid Price Requirement, Listing Rule, Delisting, Genprex, Nasdaq Capital Market, Securities Exchange Act